Electro-Optical Sciences, Inc. Announces Pricing of Initial Public Offering
28 Ottobre 2005 - 6:41PM
PR Newswire (US)
Medical Device Company Focused on Early Diagnosis of Melanoma
IRVINGTON, N.Y., Oct. 28 /PRNewswire-FirstCall/ -- Electro-Optical
Sciences, Inc. ("EOS"), a medical device company focused on the
design and development of a non-invasive, point-of-care, instrument
to assist in the early diagnosis of melanoma, today announced the
pricing of its initial public offering of 4,000,000 shares at $5.00
per share. All of the shares are being offered by EOS. The shares
will begin trading on the NASDAQ Capital Market today under the
symbol "MELA." Net proceeds to the Company from the offering will
be approximately $16.5 million and will be used to fund research
and development activities, including upcoming clinical studies and
other general corporate purposes. Closing of the offering is
expected to occur on November 2, 2005. ThinkEquity Partners LLC is
serving as sole bookrunner and co-lead manager, with Stanford Group
Company acting as co-lead manager, for the offering. A copy of the
prospectus relating to these securities may be obtained, when
available, from ThinkEquity Partners, 600 Montgomery Street, San
Francisco, CA 94111. A registration statement relating to these
securities was declared effective by the Securities and Exchange
Commission on October 28, 2005. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state. About Electro-Optical Sciences, Inc. EOS is a medical device
company focused on the design and development of a non-invasive,
point-of-care instrument to assist in the early diagnosis of
melanoma. MelaFind(R), EOS's flagship product, features a hand-held
imaging device that emits multiple wavelengths of light to capture
images of suspicious pigmented skin lesions and extract data. The
data are then analyzed against EOS's proprietary database of
melanomas and benign lesions using sophisticated algorithms in
order to provide information to the physician and produce a
recommendation of whether the lesion should be biopsied. Melanoma
is the deadliest of skin cancers, responsible for approximately 80%
of all skin cancer deaths. Unless melanoma is detected early and
excised with proper margins, the patient survival rate is poor, as
there is currently no cure for advanced stage melanoma. For more
information on EOS, visit http://www.eosciences.com/. Safe Harbor
This press release includes "forward-looking statements" within the
meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and other statements that contain words
such as "expects," "contemplates," "anticipates," "plans,"
"intends," "believes" and variations of such words or similar
expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are
based on our current beliefs or expectations and are inherently
subject to significant uncertainties and changes in circumstances,
many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results
may differ materially from our beliefs or expectations due to
economic, business, competitive, market and regulatory factors.
DATASOURCE: Electro-Optical Sciences, Inc. CONTACT: Fern Lazar,
+1-212-867-1762, ; or David Carey, (212) 867-1768, , both of Lazar
Partners Web site: http://www.eosciences.com/
Copyright